| Literature DB >> 26888741 |
Stefan Jacob1, Anja Schüffler1, Eckhard Thines1,2.
Abstract
BACKGROUND: The histidine kinase (HK) MoHik1p within the high-osmolarity glycerol (HOG) pathway is known to be the target of the fungicide fludioxonil. Treatment of the fungus with fludioxonil causes an uncontrolled hyperactivation of the pathway and cell death. In this study, we used a target-based in vivo test system with mutant strains of the rice blast fungus Magnaporthe oryzae to search for new fungicidal compounds having various target locations within the HOG pathway. Mutants with inactivated HOG signalling are resistant to fungicides having the target located in the HOG pathway.Entities:
Keywords: HOG pathway; Magnaporthe oryzae; hik1; histidine kinase; marasmic acid; osmoregulation; sesquiterpenoids; sln1
Mesh:
Substances:
Year: 2016 PMID: 26888741 PMCID: PMC5071701 DOI: 10.1002/ps.4257
Source DB: PubMed Journal: Pest Manag Sci ISSN: 1526-498X Impact factor: 4.845
IC50 from marasmic acid and fludioxonil in the wild‐type strain and the HOG mutants. The antifungal activity of marasmic acid against the M. oryzae wild type 70‐15 and the HOG mutants was compared with the activity of fludioxonil. Conidia of each strain were harvested, and growth assays were set up in H2O as described in the experimental procedures. Differences in the inhibition of different mutant strains are highlighted in grey. The highest concentration tested was 150 µg mL−1 for marasmic acid and fludioxonil
|
| Marasmic acid (IC50 in µg mL−1) | Fludioxonil (IC50 in µg mL−1) |
|---|---|---|
|
| 10.2 ± 1.5 | 4.8 ± 1 |
|
| >150 µg mL−1 | 5.2 ± 1 |
|
| 10.4 ± 1 | >150 µg mL−1 |
|
| >150 µg mL−1 | >150 µg mL−1 |
|
| >150 µg mL−1 | >150 µg mL−1 |
|
| >150 µg mL−1 | >150 µg mL−1 |
|
| >150 µg mL−1 | >150 µg mL−1 |
Inhibition zones of marasmic acid and fludioxonil on vegetatively grown wild‐type cultures and the HOG mutants on solid medium. The antifungal activity of marasmic acid against the M. oryzae wild type 70‐15 and the HOG mutants was compared with the activity of fludioxonil. Disc diffusion assays were set up on CM as described in the experimental procedures. Differences in the inhibition of different mutant strains are highlighted in grey. Three replicates were evaluated
|
| 50 µg of marasmic acid (inhibition zone in mm) | 10 µg of fludioxonil (inhibition zone in mm) |
|---|---|---|
|
| 20 ± 2 | 40 ± 3 |
|
| None | 42 ± 2 |
|
| 22 ± 1 | None |
|
| None | None |
|
| None | None |
|
| None | None |
|
| None | None |
Figure 1Phosphorylation of the MoHog1 MAPK in M. oryzae after marasmic acid treatment. Mycelium of strain M. oryzae (MoWT) was used to conduct a western analysis as described in the experimental procedures. Incubation in CM was used as negative control (K‐). Marker is a biotinylated protein ladder.
Figure 2Differences in the phosphorylation patterns of the MoHog1 MAPK in ΔMosln1 and ΔMohik1 after marasmic acid and fludioxonil treatment. Western analysis was conducted as described in the experimental methods. Incubation in CM was used as negative control (K‐) for the MoWT and each mutant strain. As representative for each negative control, we present only the MoWT probe. Marker is a biotinylated protein ladder.
Figure 3The unsaturated dialdehyde sesquiterpenoids used in this study. Structures of marasmic acid, merulidial, polygodial, isovelleral and velleral.
Comparison of the IC50 values of unsaturated dialdehyde sequiterpenoid derivatives in the wild‐type strain and the HOG mutants. The antifungal activity of merulidial, polygodial, isovelleral and velleral against the M. oryzae wild type 70‐15 and the HOG mutants was compared with the activity of marasmic acid. Conidia of each strain were harvested, and growth assays were set up in H2O as described in the experimental methods. The highest fungicide concentration in the assays was 150 µg mL−1
|
| Marasmic acid (IC50 in µg mL−1) | Merulidial (IC50 in µg mL−1) | Polygodial (IC50 in µg mL−1) | Isovelleral (IC50 in µg mL−1) | Velleral (IC50 in µg mL−1) |
|---|---|---|---|---|---|
|
| 10.2 ± 1 | 24.6 ± 2 | 5.2 ± 1 | 2.6 ± 0.5 | 2.5 ± 0 |
|
| >150 µg mL−1 | 25.4 ± 1.5 | 5.0 ± 0.5 | 2.4 ± 0.25 | 2.7 ± 0.5 |
|
| 10.2 ± 1 | 25.4 ± 1 | 5.0 ± 0 | 2.5 ± 0 | 2.5 ± 0.25 |
|
| >150 µg mL−1 | 25.0 ± 0 | 5.0 ± 0 | 2.5 ± 0.25 | 2.5 ± 0.5 |
|
| >150 µg mL−1 | 25.4 ± 2 | 4.8 ± 1 | 2.6 ± 0.5 | 2.4 ± 1 |
|
| >150 µg mL−1 | 24.6 ± 2.5 | 5.2 ± 1 | 2.5 ± 0.5 | 2.5 ± 0.5 |
|
| >150 µg mL−1 | 25.2 ± 1 | 5.0 ± 0 | 2.5 ± 1 | 2.4 ± 0.5 |
Figure 4Schematic presentation of the mode of action of marasmic acid and fludioxonil in M. oryzae. The mode of action of marasmic acid and fludioxonil in the wild‐type strain (MoWT) compared with the mutant strains ΔMosln1 and ΔMohik1 is presented. Marasmic acid treatment of the MoWT results in dephosphorylation of the phosphorelay because of interaction with MoSln1p. Therefore, the MAPK cascade MoSsk2p–MoPbs2p–MoHog1p is hyperactivated. Marasmic acid treatment of the ΔMosln1 mutant has no effect, and the phosphorylation patterns in the phosphorelay can persist adequately by functional MoHik1p. Marasmic acid treatment of the ΔMohik1 mutant has equal effects compared with the MoWT. Fludioxonil treatment of the MoWT results in dephosphorylation based on interaction with MoHik1p. For marasmic acid treatment, the MAPK cascade MoSsk2p–MoPbs2p–MoHog1p is hyperactivated. Fludioxonil treatment of the ΔMohik1 mutant has no effect, and the phosphorylation patterns in the phosphorelay can persist adequately by functional MoSln1p. Fludioxonil treatment of the ΔMosln1 mutant has equal effects compared with the MoWT.